Gilead Sciences stock is trading -8.45% below its average target price of $125.19 after marking a 1.9% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $98.0 to $145.0 per share.
Gilead Sciences's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.4%. The stock's short ratio is 2.79. At 0.1%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 90.8%. In conclusion, we believe there is mixed market sentiment regarding Gilead Sciences.
Institutions Invested in Gilead Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 10% | 119,364,226 | $13,680,334,014 |
| 2025-06-30 | Blackrock Inc. | 9% | 114,879,922 | $13,166,387,930 |
| 2025-06-30 | FMR, LLC | 5% | 59,955,377 | $6,871,485,794 |
| 2025-06-30 | State Street Corporation | 5% | 59,188,160 | $6,783,555,053 |
| 2025-06-30 | Capital World Investors | 4% | 46,303,299 | $5,306,821,126 |
| 2025-06-30 | Wellington Management Group, LLP | 3% | 37,530,510 | $4,301,371,774 |
| 2025-06-30 | Capital Research Global Investors | 3% | 31,097,679 | $3,564,105,009 |
| 2025-06-30 | Dodge & Cox Inc | 2% | 30,818,322 | $3,532,087,903 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 29,207,662 | $3,347,490,159 |
| 2025-06-30 | Price (T.Rowe) Associates Inc | 2% | 23,586,692 | $2,703,270,784 |
